Please assess the completion status of the following clinical trial:

Trial Title: Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women are eligible to participate if they are 40 years or older and have been menopausal (had no menstrual bleeding during the past 12 months)~Exclusion Criteria:~* History of bilateral mastectomy, osteoporosis or renal impairment.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Letrozole, Breast enhancement, Safety (Type: EXPERIMENTAL): Single arm of healthy postmenopausal women who received baseline diagnostic MRI will receive letrozole of 12.5 mg/day orally for three successive days. A second post treatment breast MRI is done right after receiving the three days of letrozole treatment and within one month after the first MRI .

Based on this trial design, predict the completion outcome and termination type (if applicable).